लोड हो रहा है...
Treatment sequencing in metastatic castrate-resistant prostate cancer
Six different treatments have demonstrated improved survival in phase III trials targeted to patients with metastatic castration-resistant prostate cancer (mCRPC). Front-line therapeutic options for mCRPC include docetaxel, sipuleucel-T, abiraterone and radium-223. Post-docetaxel options include cab...
में बचाया:
| मुख्य लेखकों: | , |
|---|---|
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
Medknow Publications & Media Pvt Ltd
2014
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4023372/ https://ncbi.nlm.nih.gov/pubmed/24675654 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/1008-682X.126378 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|